A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

计划入组 150 人 · 首次发布于 2025 年 6 月 13 日

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

计划入组 138 人 · 首次发布于 2026 年 5 月 12 日

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

计划入组 867 人 · 首次发布于 2021 年 12 月 20 日

AKY-1189

[64Cu]Cu-XT117

64-Cooper SARTATE

CU CHEMIE UETIKON GmbH

Germany

CU Anschutz Medical Campus

United States

CHULALONGKORN UNIVERSITY

Thailand

FDA Clears Phase 1b Trial for Novel Nectin-4 Targeted Radiopharmaceutical AKY-1189 Across Multiple Cancer Types

Novel Mini-Protein AKY-1189 Shows Promise in Targeted Radiation Delivery for Multiple Cancer Types

Aktis Oncology's First-in-Class Nectin-4 Radiopharmaceutical AKY-1189 Shows Promising Tumor Uptake Across Multiple Cancer Types